Ewopharma to commercialize Eisai drugs in Central Eastern Europe

23 June 2017

Privately-held Swiss drugmaker Ewopharma revealed yesterday that, as of April 1 this year, it has acquired the rights to commercialize several of Japanese pharma major Eisai's (TYO: 4523) products in 11 countries in Central and Eastern Europe (CEE).

Ewopharma will commercialize cancer drug Halaven (eribulin mesylate) in nine countries within the European Union (Bulgaria, Croatia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania and Slovenia) and in two countries outside of the EU (Bosnia & Herzegovina and Serbia). Ewopharma will also commercialize Targretin (bexarotene), also for cancer, in Hungary and Poland as well as epilepsy drug Zonegran (zonisamide) in Hungary.

Ewopharma will be responsible for all aspects of pricing, reimbursement, marketing and distribution, while Eisai will supply product and also provide significant product training and support across the relevant brands.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK